Date: 2018-06-27
Type of information: Nomination
Compound:
Company: Adicet bio (USA - CA)
Therapeutic area: Cancer - Oncology - Immunological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 27, 2018, Adicet Bio announced that it has appointed Stewart Abbot as its Chief Scientific Officer. Dr. Abbot brings extensive industry experience in the research, early product development and clinical translation of cell-based therapies. Prior to Adicet, he served as Chief Development Officer at Fate Therapeutics where he oversaw all aspects of late-stage research and development of hematopoietic and induced pluripotent stem cell-based immunotherapeutics. Dr. Abbot's previous roles included Executive Director of Integrative Research at Celgene Cellular Therapeutics (CCT) where he led Integrative Research activities that encompassed technology and product scouting, alliance management and business development activities, including initiation of engineered T cell programs. As Senior Director of Research at CCT, his group developed novel therapeutic candidates based on hematopoietic stem cells and human placenta-derived cells and initiated clinical trials for placental cells. He also headed the Molecular and Cellular Biology research laboratory at General Electric's Global Research Center in Albany, N.Y. Dr. Abbot holds a B.Sc. in Biological Sciences (Edinburgh), M.Sc. in Biomedical Engineering (Glasgow) and Ph.D. in Pathology (London).
Financial terms:
Latest news:
Is general: Yes
